Local Coverage Determination (LCD)

Micro-Invasive Glaucoma Surgery (MIGS)

L38301

Expand All | Collapse All

Contractor Information

LCD Information

Document Information

LCD ID
L38301
LCD Title
Micro-Invasive Glaucoma Surgery (MIGS)
Proposed LCD in Comment Period
N/A
Source Proposed LCD
DL38301
Original Effective Date
For services performed on or after 03/23/2020
Revision Effective Date
For services performed on or after 10/03/2021
Revision Ending Date
N/A
Retirement Date
N/A
Notice Period Start Date
08/19/2021
Notice Period End Date
10/02/2021
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2021 American Dental Association. All rights reserved.

Copyright © 2013 - 2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@aha.org.

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1862(a)(1)(D) refers to limitations on items or devices that are investigational or experimental.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

CMS Publications:

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 14,

10 Coverage of Medical Devices

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 23,

30 Services paid under the Medicare Physicians Fee Schedule

CMS Publication 100-08, Medicare Program Integrity Manual, Chapter 13,

5.1 Reasonable and necessary provisions in LCDs

7.1 Evidence supporting LCDs.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

This LCD addresses use of a group of surgical procedures for glaucoma referred to as Micro-Invasive Glaucoma surgery (MIGS). Noridian considers up to two iStent aqueous drainage devices, or one Hydrus device per eye medically reasonable and necessary for the treatment of adults with mild or moderate open-angle glaucoma and a cataract when the individual is currently being treated with an ocular hypotensive medication and the procedure is being performed in conjunction with cataract surgery. According to CPT®, in this setting a 'device' is a 'stent'. Therefore, 'two iStent aqueous drainage devices' means two (initial generation) iStents or one pair of stents that are contained in iStent Inject.

One XEN45 device per eye is covered for the management of refractory glaucoma, defined as prior failure of filtering/cilioablative procedure and/or uncontrolled Intraocular Pressure (IOP) on maximally tolerated medical therapy. XEN45 insertion must be performed by an ophthalmologist with experience with trabeculectomy and bleb management.

Summary of Evidence

Primary open-angle glaucoma (POAG) has a prevalence in the US of 2% of adults over 40 years old, or about 2.2 million people, and is expected to increase to 3.3 million in 2020 as the population ages.1 POAG is a chronic, progressive optic neuropathy in adults in which there is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons. It is associated with an increased IOP, due to a buildup of aqueous fluid within the eye which can lead to visual field loss and optic nerve damage, usually without any associated pain or discomfort. The increased IOP is secondary to an imbalance between aqueous fluid secretion and fluid outflow despite an open angle. Nearly 40% of those with otherwise characteristic POAG may not have elevated IOP measurements.1

In the primary (conventional) outflow pathway from the eye, aqueous humor passes through the trabecular meshwork, enters a space lined with endothelial cells (Schlemm canal), drains into collector channels, and then into the aqueous veins. Increases in resistance in the trabecular meshwork or the inner wall of the Schlemm canal can disrupt the balance of aqueous humor inflow and outflow, resulting in an increase in IOP and glaucoma risk.

The goal in POAG is to reduce the IOP to slow the development of optic nerve damage. The IOP can be reduced by medical treatment or surgery, alone or in combination. IOP above 21 mm Hg has been shown to increase rates of visual field loss. However, because of the differences in susceptibility to pressure-related disc damage among POAG patients, pressure-lowering treatments are aimed at achieving a lower “target” pressure individualized to each patient’s baseline IOP in which glaucomatous damage occurred.

When the maximum tolerated medical therapy fails to control progression of glaucomatous optic neuropathy, surgical care is considered the next treatment option. More traditional filtration surgery includes trabeculectomy (including ExPress shunt) and aqueous drainage implants (Ahmed, Baerveldt, Molteno). Trabeculectomy uses the patient’s own sclera to create a fistula to the subconjunctival space over the sclera superiorly. Aqueous drainage implants use silicone/plastic tubing and large plates to shunt aqueous to the subconjunctival space in the equatorial region of the eyeball.

While IOP outcomes are generally worse with aqueous drainage implants compared with trabeculectomy, complications such as hypotony (low pressure), and postoperative infection are reduced. However, failure rates are similar (approximately 10% of devices fail annually), and shunts still have complications, including corneal endothelial failure and erosion of the overlying conjunctiva.

The term micro-invasive or minimally invasive glaucoma surgery (MIGS) refers to a group of newer surgical procedures that are frequently performed using an ab interno (from inside the eye) approach via gonioscopic guidance and involve minimal trauma to ocular tissues. In contrast traditional filtration surgeries such as trabeculectomy and aqueous tube shunt, are typically performed from an external approach.

Compared with traditional filtration surgery, MIGS holds the promise of faster recovery time and less severe complications, and it is this potentially improved safety profile that opened up the indications for MIGS to include patients with early-stage glaucoma to reduce the burden of medications and problems with compliance (due to eye drop application difficulty, cost, cosmetic effects, and frequency).

Another area of investigation is patients with glaucoma who require cataract surgery. An advantage of ab interno shunts is that they may be inserted into the same incision and at the same time as cataract surgery. In addition, most MIGS devices do not preclude subsequent trabeculectomy if needed. Therefore, health outcomes of interest are the IOP lowering achieved, reduction in medication use, ability to convert to trabeculectomy, complications, and device durability.

There are five Food and Drug Administration (FDA) approved/cleared micro-invasive surgical stents:

(Initial Generation) iStent Trabecular Micro-Bypass Stent (2011) a small (1 mm x 0.5 mm) L-shaped titanium device that is inserted into the Schlemm canal to augment the natural outflow system

CyPass Micro-Stent System (July, 2016) a 6.35 mm long fenestrated microstent made of bio compatible polypeptide inserted into the supraciliary space, thus using an alternative outflow system

XEN45 Glaucoma Treatment System (November 2016) a 6 mm long porcine-derived gelatin stent inserted into the subconjunctival space, bypassing the natural outflow system

Hydrus Microstent (August 2018) an 8 mm nitinol, crescent-shaped microstent with alternating spines of support and windows to provide outflow, also place into the Schlemm canal

iStent inject (June, 2018), two heparin-coated titanium stents (each having 0.23 mm diameter x 0.36 mm height, 0.08 mm central lumen diameter and four 0.05 mm side outlets to allow for multidirectional outflow), both instered into the Schlemm canal using a pre-loaded auto-injection trocar.

The (initial generation) iStent, iStent inject, Hydrus and CyPass were FDA approved (CyPass was recalled by FDA for safety concerns in September 2018, and remains so) for use in combination with cataract surgery to reduce IOP in adults with mild or moderate OAG and a cataract that are currently being treated with medication to reduce IOP.

XEN45 was granted FDA clearance for the management of refractory glaucoma, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. The published pivotal trial data for each, constituting the main evidentiary support, is summarized in the attached table. MIGS Pivotal Trials 

Analysis of Evidence (Rationale for Determination)

According to the 2020 AAO POAG Preferred Practice Pattern (PPP), the "potential benefits of a combined procedure (cataract extraction with Intraocular Lens (IOL) implantation and glaucoma surgery) are protection against the IOP rise that may complicate cataract surgery alone, the possibility of achieving long-term glaucoma control with a single operation, and elimination of the risk of bleb failure with subsequent cataract surgery when glaucoma surgery is performed first. Therefore, an ophthalmologist may reasonably choose to perform a combined surgery because of these perceived advantages to an individual patient."1

In summary, Noridian considers up to two stents (either two initial generation iStents, or the pair of two stents included in iStent inject*, or one Hydrus device per eye medically reasonable and necessary for the treatment of adults with mild or moderate open-angle glaucoma and a cataract when the individual is currently being treated with an ocular hypotensive medication and the procedure is being performed in conjunction with cataract surgery. In that setting these procedures offer the potential for a reduction in IOP, decreased dependence on glaucoma medications, and an excellent safety profile. However, their role within the glaucoma treatment algorithm continues to be clarified and differs from the role of more invasive, external filtration glaucoma surgeries such as trabeculectomy or aqueous drainage implants. Therefore, all other indications are considered not reasonable and necessary at this time, including insertion of additional devices beyond what is stated, regardless of method, since a statistical benefit has not been demonstrated,27 especially in conjunction with cataract surgery.

The XEN45 device received FDA 510(k) clearance based on having a similar mechanism (subconjunctival pathway) as “gold standard” filtration procedures (trabeculectomy and tube shunts), demonstrating “substantial equivalence” in the pivotal prospective study of patients with refractory glaucoma.17 Equivalency was further established by a relatively large retrospective cohort study comparing XEN45 with trabeculectomy, finding “no detectable difference in risk of failure and safety profiles”.11 In addition, the American Glaucoma Society (AGS), the New York State Ophthalmological Society (NYSOS), and numerous glaucoma experts wrote Noridian to support XEN45 as a minimally invasive method that, “would improve the access of older patients with refractory glaucoma to surgical care with reduction in post-operative discomfort, shorter post-operative disability, equivalent efficacy and safety.”

Noridian considers one XEN45 device per eye medically reasonable and necessary for the management of refractory glaucoma, defined as prior failure of filtering/cilioablative procedure and/or uncontrolled IOP on maximally tolerated medical therapy. XEN45 insertion must be performed by an ophthalmologist with experience with trabeculectomy and bleb management.

General Information

Associated Information

N/A

Sources of Information

N/A

Bibliography
  1. American Academy of Ophthalmology (AAO), Glaucoma Panel. Primary Open-Angle Glaucoma. Preferred Practice Pattern. San Francisco, CA: AAO; 2020. Accessed 06/29/2021 http://www.aaojournal.org/article/S0161-6420(15)01276-2/pdf.
  2. Samuelson TW, Katz LJ, Wells JM, et al. US iStent Study Group. Randomized Evaluation of the Trabecular Micro-Bypass Stent with Phacoemulsification in Patients with Glaucoma and Cataract. Ophthalmology. 2011;118(3):459-67.
  3. Craven ER, Katz LJ, Wells JM, et al. iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up. J Cataract Refract Surg. 2012 Aug;38(8):1339-45.
  4. Vold S, Ahmed II, Craven ER, et al. CyPass Study Group. Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts. Ophthalmology. 2016 Aug 6. pii: S0161-6420(16)30500-0.
  5. Stalmans I, Vera V. Evaluation of the XEN Implant in Patients With Moderate Primary Open-Angle Glaucoma: 1-Year Results. Abstract presented at the European Glaucoma Society 2016 Congress (EGS), June 19-22, 2016, Prague, Czech Republic.
  6. Anthem policy SURG.00103. Intraocular Anterior Segment Aqueous Drainage Devices (without extraocular reservoir). Last accessed 3/30/17.
  7. Unitedhealthcare policy 2017T0443S. Glaucoma Surgical Treatments. Last accessed 3/30/17.
  8. BCBSMA policy 223. Aqueous Shunts and Stents for Glaucoma. Last accessed 3/30/17.
  9. Aetna policy 0484. Glaucoma Surgery. Last accessed 3/30/17
  10. BCBS policy A.9.03.21. Aqueous Shunts and Stents for Glaucoma. Last accessed 3/30/17.
  11. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology. 2017;124(11):1579-1588.
  12. Galal A, Bilgic A, Eltanamly R, Osman A. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. J Ophthalmol. 2017;2017:5457246.
  13. De Gregorio A, Pedrotti E, Russo L, Morselli S. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2017:1-6. doi: 10.1007/s10792-017-0571.
  14. Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsification and Xen 45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016;91(9):415-421.
  15. Pinto Ferreira N, Abegã Pinto L, Marques-Neves C. Xen gel stent internal ostium occlusion: ab-interno revision. J Glaucoma. 2017;26(4):e150–e152.
  16. Hohberger B, Welge-LüBen UC, Lämmer R. ICE-Syndrome: A case report of implantation of a microbypass Xen gel stent after DMEK transplantation. J Glaucoma. 2017;26(2):e103–e104.
  17. Grover DS, Flynn WJ, Bashford KP, et al. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. Am J Ophthalmol. 2017;183:25-36.
  18. Katz LJ, Erb C, Carceller GA, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clinical Ophthalmology. 2015;9:2313-2320.
  19. Donnenfeld ED, Solomon KD, Voskanyan L, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clinical Ophthalmology. 2015;9:2057-2065.
  20. Berdahl J, Voskanyan L, Myers JS, et al. Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up. Clinical & Experimental Ophthalmology. 2017;45(8):797-802.
  21. Ferguson TJ, Berdahl JP, Schweitzer JA, Sudhagoni R. Evaluation of a trabecular micro-bypass stent in pseudophakic patients with open-angle glaucoma. Journal of glaucoma. 2016;25(11):896-900.
  22. Garcia-Feijoo J, Rau M, Grisanti S, et.al. Supraciliary micro-stent implantation for open-angle glaucoma failing topical therapy: 1-year results of a multicenter study. Am J Ophthalmol. 2015;159(6):1075–1081.
  23. Roelofs K, Arora S, Dorey MW. Implantation of 2 trabecular microbypass stents in a patient with primary open-angle glaucoma refractory to previous glaucoma-filtering surgeries. Journal of Cataract & Refractive Surgery. 2014;40(8):1322-1324.
  24. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology. 2018.
  25. Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma. Ophthalmology. 2015;122(7):1283-1293.
  26. Samuelson TW, Sarkisian SR, Jr., Lubeck DM, et al. Prospective, Randomized, Controlled Pivotal Trial of iStent inject Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. Ophthalmology. 2019.
  27. Katz LJ, Erb C, Carceller Guillamet A, et al. Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes. Clin Ophthalmol. 2018;12:255-262.

Revision History Information

Revision History DateRevision History NumberRevision History ExplanationReasons for Change
10/03/2021 R3

Typographical and verbiage changes were made throughout the document for clarification.

  • Provider Education/Guidance
02/15/2021 R2

The LCD language in the Coverage paragraph was updated for clarity to show coverage for use of two iStent aqueous drainage devices per eye. Each injector is loaded with two devices and confusion was occurring as to whether the injector device was limited to one or if only one iStent was allowed.

  • Provider Education/Guidance
03/23/2020 R1

The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.
    )

Associated Documents

Attachments
N/A
Related National Coverage Documents
N/A
Public Versions
Updated On Effective Dates Status
08/12/2021 10/03/2021 - N/A Currently in Effect You are here
02/18/2021 02/15/2021 - 10/02/2021 Superseded View
01/30/2020 03/23/2020 - 02/14/2021 Superseded View
01/23/2020 03/23/2020 - N/A Superseded View

Keywords

N/A

Read the LCD Disclaimer